Market cap of Zomedica Corp. [ZOM] reaches 450.80M – now what?


Zomedica Corp. [AMEX: ZOM] closed the trading session at $0.48 on 11/19/21. The day’s price range saw the stock hit a low of $0.45, while the highest price level was $0.48. The company report on November 12, 2021 that Zomedica Announces Third Quarter 2021 Financial Results.

Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the three and nine months ended September 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). Third quarter results do not include operations of PulseVet which were acquired on October 1, 2021.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Larry Heaton, Chief Executive Officer of Zomedica, stated that, “During the third quarter the team at Zomedica continued building the installed base of TRUFORMA® instruments through our Customer Appreciation Program (CAP), which provides select customers with an instrument at no charge as long as they agree to purchase assay cartridges. Customer response to this program has been encouraging, with 144 customers enrolled to date, and we plan to continue offering it through the end of the year. We expect revenue from these CAP program customers to build sequentially as they utilize cartridges currently available, and new ones as they are released to market. We continue to work with our partner, Qorvo Biotechnologies, to develop new assays for the TRUFORMA® instrument and expect to release several new assays to market in 2022.

The stocks have a year to date performance of 107.72 percent and weekly performance of -11.13 percent. The stock has been moved at -39.38 percent over the last six months. The stock has performed -6.04 percent around the most recent 30 days and changed -3.23 percent over the most recent 3-months.

If compared to the average trading volume of 27.29M shares, ZOM reached to a volume of 13439032 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Zomedica Corp. [ZOM]:

The Average True Range (ATR) for Zomedica Corp. is set at 0.03, with the Price to Sales ratio for ZOM stock in the period of the last 12 months amounting to 8614.42. The Price to Book ratio for the last quarter was 1.71, with the Price to Cash per share for the same quarter was set at 0.29.

ZOM stock trade performance evaluation

Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.13. With this latest performance, ZOM shares dropped by -6.04% in over the last four-week period, additionally sinking by -39.38% over the last 6 months – not to mention a rise of 229.89% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 43.20, with the RSI for the last a single of trading hit 41.22, and the three-weeks RSI is set at 44.23 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.5180, while it was recorded at 0.4840 for the last single week of trading, and 0.9594 for the last 200 days.

Zomedica Corp. [ZOM]: An insightful look at the core fundamentals

Return on Total Capital for ZOM is now -50.05, given the latest momentum, and Return on Invested Capital for the company is -51.08. Return on Equity for this stock declined to -51.94, with Return on Assets sitting at -48.09. When it comes to the capital structure of this company, Zomedica Corp. [ZOM] has a Total Debt to Total Equity ratio set at 2.96. Additionally, ZOM Total Debt to Total Capital is recorded at 2.88, with Total Debt to Total Assets ending up at 2.82. Long-Term Debt to Equity for the company is recorded at 2.13, with the Long-Term Debt to Total Capital now at 1.68.

Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 56.10 and a Current Ratio set at 56.40.

Earnings per share (EPS) analysis for Zomedica Corp. [ZOM] stock

With the latest financial reports released by the company, Zomedica Corp. posted -0.03/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.

>> 7 Top Picks for the Post-Pandemic Economy <<

Zomedica Corp. [ZOM]: Insider Ownership positions

There are presently around $58 million, or 14.60% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: VANGUARD GROUP INC with ownership of 41,454,324, which is approximately -2.463% of the company’s market cap and around 0.10% of the total institutional ownership; STATE STREET CORP, holding 22,797,831 shares of the stock with an approximate value of $10.92 million in ZOM stocks shares; and BLACKROCK INC., currently with $8.68 million in ZOM stock with ownership of nearly 4.552% of the company’s market capitalization.

Positions in Zomedica Corp. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 44 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 9,828,554 shares. Additionally, 44 investors decreased positions by around 20,199,007 shares, while 36 investors held positions by with 90,345,703 shares. The mentioned changes placed institutional holdings at 120,373,264 shares, according to the latest SEC report filing. ZOM stock had 20 new institutional investments in for a total of 2,754,498 shares, while 16 institutional investors sold positions of 14,729,530 shares during the same period.